As of November 6, 2026, Ascendis Pharma A/S is a publicly traded company (Nasdaq: ASND); its largest reported holder is T. Rowe Price, with 9.9% on Schedule 13G of May 7, 2026, then Westfield Capital Management Company, L.P. (8.48%). The largest insider holding is Mikkelsen Jan Moller, a director, with 453,403 shares (0.73% of shares outstanding), per Form 3 of March 18, 2026 (Schedule 13G, May 7, 2026).
Is this your company?
About to sign with, pay or invest in Ascendis Pharma A/S? See the free Snapshot first.
Free to see. No signup.
Is Ascendis Pharma A/S a real, registered company?
- Ascendis Pharma A/S files with the SEC under CIK 1612042 (its SEC filings).
- Its shares are listed under the ticker ASND on Nasdaq (SEC company record).
- Incorporated in G7, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ASCENDIS PHARMA AS in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Ascendis Pharma A/S' owners and officers?
Ascendis Pharma A/S: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 5.2% |
| Schedule 13G/A, 2026-08-13 | Artisan Partners Asset Management Inc. | 4.2% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 6% |
| Schedule 13G/A, 2026-05-14 | Capital International Investors | 3.2% |
| Schedule 13G, 2026-05-07 | T. Rowe Price Investment Management, Inc. | 9.9% |
| Schedule 13G/A, 2026-05-07 | T. Rowe Price Investment Management, Inc. | 10.5% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 6.6% |
| Schedule 13G/A, 2026-02-11 | Westfield Capital Management Company, L.P. | 8.48% |
| Schedule 13G/A, 2026-02-03 | Artisan Partners Asset Management Inc. | 5.2% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 7.8% |
| Schedule 13G/A, 2025-11-14 | T. Rowe Price Investment Management, Inc. | 4.8% |
| Schedule 13G/A, 2025-08-14 | T. Rowe Price Investment Management, Inc. | 6.4% |
Questions about who owns Ascendis Pharma A/S
Who owns Ascendis Pharma A/S?
On this page, 4 holders' latest ownership filings report 5% or more of Ascendis Pharma A/S: T. Rowe Price Investment Management, Inc. (9.9%, Schedule 13G, filed 2026-05-07), Westfield Capital Management Company, L.P. (8.48%, Schedule 13G/A, filed 2026-02-11), Janus Henderson Group PLC (6%, Schedule 13G/A, filed 2026-05-15) and Fmr LLC (5.2%, Schedule 13G/A, filed 2026-11-05).
Who are the largest shareholders of Ascendis Pharma A/S?
By the share each holder's latest filing reports, the largest holders of Ascendis Pharma A/S on this page are T. Rowe Price Investment Management, Inc. (9.9%), Westfield Capital Management Company, L.P. (8.48%) and Janus Henderson Group PLC (6%).
When did T. Rowe Price Investment Management, Inc. buy into Ascendis Pharma A/S?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 6.4%; its latest, Schedule 13G filed 2026-05-07, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Ascendis Pharma A/S?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ascendis Pharma A/S: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ascendis Pharma A/S covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Ascendis Pharma A/S shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 453,403 shares (0.73% of shares outstanding), 384,933 held directly and 68,470 indirectly (Form 3, 2026-03-18).
- Kennett Sprogoe: 19,570 shares (0.03% of shares outstanding), 19,460 held directly and 110 indirectly (Form 3, 2026-03-18).
- , the executive vice president and chief admin officer: 19,460 shares (0.03% of shares outstanding) (Form 3, 2026-03-18).
- , the chief financial officer and executive vice president: 4,367 shares (0.01% of shares outstanding) (Form 4, 2026-06-02).
- , a director: 4,000 shares (0.01% of shares outstanding) (Form 4, 2026-09-03).
Shares outstanding: 61,977,408 as of 2025-12-31, from the company's latest SEC cover page.
How much has Ascendis Pharma A/S raised?
No fundraising or offering filing from Ascendis Pharma A/S is on file with us.
Keep reading
More on Ascendis Pharma A/S and the records around it.
Ascendis Pharma A/S elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Westfield Capital Management Company, L.P. also filed stake reports on 2 other companies: IMAX CORP (Jun 2026), BICYCLE THERAPEUTICS PLC (Mar 2026)
- Artisan Partners Asset Management Inc. also filed stake reports on 16 other companies: AXALTA COATING SYSTEMS LTD. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), RADWARE LTD. (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ascendis-pharma-as